ProPhase Labs (NASDAQ:PRPH – Get Free Report) and Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.
Earnings and Valuation
This table compares ProPhase Labs and Enliven Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ProPhase Labs | $5.06 million | 0.18 | -$53.36 million | ($3.90) | -0.04 |
| Enliven Therapeutics | N/A | N/A | -$89.02 million | ($1.84) | -16.14 |
Profitability
This table compares ProPhase Labs and Enliven Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ProPhase Labs | -825.01% | -482.05% | -88.90% |
| Enliven Therapeutics | N/A | -24.88% | -23.96% |
Institutional & Insider Ownership
9.4% of ProPhase Labs shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 9.6% of ProPhase Labs shares are held by company insiders. Comparatively, 25.9% of Enliven Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Volatility & Risk
ProPhase Labs has a beta of -0.54, meaning that its share price is 154% less volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and target prices for ProPhase Labs and Enliven Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ProPhase Labs | 1 | 0 | 0 | 0 | 1.00 |
| Enliven Therapeutics | 1 | 0 | 4 | 0 | 2.60 |
Enliven Therapeutics has a consensus price target of $41.00, suggesting a potential upside of 38.09%. Given Enliven Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Enliven Therapeutics is more favorable than ProPhase Labs.
Summary
Enliven Therapeutics beats ProPhase Labs on 10 of the 13 factors compared between the two stocks.
About ProPhase Labs
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
About Enliven Therapeutics
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.
